Venetoclax is a B-cell lymphoma 2 (BCL-2) inhibitor and plays an important role in the clinical treatment of hematological malignancies, such as acute myeloid leukemia and chronic lymphocytic leukemia. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.